Woodline Partners’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.26M | Buy |
149,267
+12,784
| +9% | +$622K | 0.04% | 490 |
|
|
2025
Q1 | $4.64M | Buy |
136,483
+34,883
| +34% | +$1.19M | 0.03% | 526 |
|
|
2024
Q4 | $4M | Buy |
101,600
+1,600
| +2% | +$63K | 0.03% | 527 |
|
|
2024
Q3 | $4.7M | Sell |
100,000
-26,839
| -21% | -$1.26M | 0.04% | 392 |
|
|
2024
Q2 | $6.85M | Sell |
126,839
-36,738
| -22% | -$1.98M | 0.07% | 301 |
|
|
2024
Q1 | $11.1M | Buy |
163,577
+113,544
| +227% | +$7.74M | 0.1% | 245 |
|
|
2023
Q4 | $3.13M | Sell |
50,033
-50,379
| -50% | -$3.15M | 0.03% | 354 |
|
|
2023
Q3 | $4.56M | Buy |
100,412
+50,412
| +101% | +$2.29M | 0.05% | 322 |
|
|
2023
Q2 | $2.81M | Buy |
+50,000
| New | +$2.81M | 0.03% | 381 |
|
|
2022
Q2 | – | Sell |
-189,126
| Closed | -$11.9M | – | 813 |
|
|
2022
Q1 | $11.9M | Buy |
189,126
+179,759
| +1,919% | +$11.3M | 0.19% | 153 |
|
|
2021
Q4 | $710K | Buy |
+9,367
| New | +$710K | 0.01% | 535 |
|